Login to Your Account



Neurocrine Gets Positive Data In 'Most Important' Indiplon Studies

By Kim Coghill


Thursday, March 25, 2004
Neurocrine Biosciences Inc. released favorable data from two long-term Phase III studies proving that its insomnia candidate, indiplon, remains effective for at least three months and is associated with quality-of-life improvements for its users. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription